(UroToday.com) The 2025 European Association of Urology (EAU) Annual Congress held in Madrid, Spain between March 21 st and 24 th 2025, was host to a thematic session on intravesical therapy for ...

PSMA and Beyond 2025 antibody drug development (ADC) in prostate cancer, ADC program in advance prostate cancer, PSMA expression, ...

PSMA and Beyond 2025 PSMAfore trial, SPLASH trial, ECLIPSE trial, PSMA radioligand therapy, PSMAfore compared to SPLASH, SPLASH LuPSMA arm, PSMAfore LuPSMA arm, ProstACT GLOBAL.

ASCO 2025 fully automated PSMA PET quantification, overall survival in patients undergoing 177Lu PSMA therapy, PSMA SUVmean, metastatic castrate resistant prostate cancer (mCRPC).

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Morris provided a summary of the PSMAfore trial in progress (NCT04689828). This ...

ASCO 2025 ProstACT Global, phase 3 study of 177Lu-rosptamab + standard of care versus standard of care alone, metastatic castration-resistant prostate cancer (mCRPC).

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured a PSMA session and a presentation by Dr. Wolfgang Fendler discussing PSMA-PET for overall survival outcome risk stratification of ...